A field-collected multiresistant strain of Tetranychus urticae Koch exhibiting high resistance to bifenthrin was investigated in comparison with a susceptible laboratory strain. The esterase inhibitor S,S,S-tributyl-phosphorotrithioate (DEF) was able strongly to synergise bifenthrin toxicity in the resistant strain. Optimal conditions for determining esterase activities in T. urticae were determined, and a higher esterase activity towards several artificial substrates was found in this resistant strain, which had a preference for hydrolysing 4-nitrophenyl butyrate. Bifenthrin was able to bind the active centres of T. urticae esterases in vitro, as was determined after competition experiments by a Dixon plot, revealing a higher affinity of bifenthrin in the resistant strain. Bifenthrin-hydrolysing activity in the resistant and susceptible strains was examined in vitro and quantified with gas chromatography. A 7.2-fold higher metabolising rate was found in the resistant strain.
No takes yet. Share an insight, caveat, or question.
Leeuwen et al. (2006) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: